China’s much-anticipated update of its National Reimbursement Drug List (NRDL) presents a mixed bag for overseas pharma. Overall, there were few surprises in China’s continued prioritisation…
By
China’s efforts to rein in high medicine prices seem to have hit warp speed. In the last two years…
By
Asia’s emerging markets – such as Indonesia, Vietnam, and the Philippines – may provide a significant growth opportunity of…
By Asia is seeing increasing convergence between some of its major markets and the United States and Europe, according to…
By
Takeda’s pursuit of UK pharma major Shire has not only made headlines over the last few months, it also…
By
On 3 April, the Trump administration threatened to place tariffs of 25% on more than 1,300 Chinese goods worth…
By
Earlier this month, China took an axe to a swathe of red tape that has infuriated overseas drugmakers for years: the…
By
In mid-July, China’s Ministry of Human Resources and Social Security (MoHRSS) announced that it would add another 36 medicines…
By
Hong Kong’s drug reimbursement process has come under renewed scrutiny following a public outcry over the death of a…
By